The fact
The REFIT2 study, published in The Lancet, includes 165 patients in phase 3.
This therapy could become a standard treatment for severe cases.
Click the link to read an article on the topic:
The REFIT2 study, published in The Lancet, includes 165 patients in phase 3.
This therapy could become a standard treatment for severe cases.